Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion

[1]  E. Tavares,et al.  Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer , 2012, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[2]  K. Buhman,et al.  Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification , 2011, Clinical & Experimental Metastasis.

[3]  L. Tao,et al.  Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. , 2010, Cellular signalling.

[4]  D. Guo,et al.  Microtubule-Binding Natural Products for Cancer Therapy , 2010, Planta Medica.

[5]  I. Schonn,et al.  Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage , 2010, Apoptosis.

[6]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[7]  M. Blagosklonny,et al.  Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis , 2008, Oncogene.

[8]  D. Maria,et al.  Drug-targeting in combined cancer chemotherapy: Paclitaxel and etoposide derivatives associated with a lipidic nanoemulsion promote tumor regression in mice , 2008 .

[9]  G. V. van Muijen,et al.  Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma , 2007, International journal of cancer.

[10]  D. Maria,et al.  Evaluation in melanoma‐bearing mice of an etoposide derivative associated to a cholesterol‐rich nanoemulsion , 2006, The Journal of pharmacy and pharmacology.

[11]  R. Maranhão,et al.  Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers , 2006, Cancer Chemotherapy and Pharmacology.

[12]  R. Maranhão,et al.  Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE , 2006, Cancer Chemotherapy and Pharmacology.

[13]  R. Maranhão,et al.  Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. , 2005, Gynecologic oncology.

[14]  D. Fernandes,et al.  Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies , 2005, Cancer Chemotherapy and Pharmacology.

[15]  C. Lieu,et al.  Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells. , 2005, Life sciences.

[16]  R. Curi,et al.  Effects on Walker 256 tumour of carmustine associated with a cholesterol‐rich microemulsion (LDE) , 2004, The Journal of pharmacy and pharmacology.

[17]  D. Fernandes,et al.  Use of a cholesterol‐rich microemulsion that binds to low‐density lipoprotein receptors as vehicle for etoposide , 2003, The Journal of pharmacy and pharmacology.

[18]  K. Wasan,et al.  A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[19]  A. Buzaid,et al.  Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients , 2002, Cancer Chemotherapy and Pharmacology.

[20]  J. Pinotti,et al.  Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. , 2001, Gynecologic oncology.

[21]  T. Fojo,et al.  Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity , 2001, Oncogene.

[22]  G. Moalem,et al.  THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma. , 1999, Journal of immunotherapy.

[23]  M. Hirata,et al.  Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. , 1999, Biochimica et biophysica acta.

[24]  C. Chi,et al.  Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. , 1998, Anticancer research.

[25]  S. Horwitz,et al.  Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.

[26]  H. Schmidt,et al.  Low-density lipoprotein receptor mRNA in human breast cancer cells: Influence by PKC modulators , 1997, Breast Cancer Research and Treatment.

[27]  H. Oppelaar,et al.  Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. , 1996, British Journal of Cancer.

[28]  J. C. Meneghetti,et al.  Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. , 1994, Cancer research.

[29]  M. Hirata,et al.  Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein , 1993, Lipids.

[30]  O. Larsson,et al.  Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. , 1992, Cancer research.

[31]  S. Yamashita,et al.  Hypocholesterolaemic factor from gallbladder cancer cells , 1990, The Lancet.

[32]  G. Gahrton,et al.  Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Angelin,et al.  HYPOCHOLESTEROLAEMIA AND INCREASED ELIMINATION OF LOW-DENSITY LIPOPROTEINS IN METASTATIC CANCER OF THE PROSTATE , 1989, The Lancet.

[34]  N. Le,et al.  Increased low-density-lipoprotein catabolism in myeloproliferative disorders. , 1982, Annals of internal medicine.

[35]  M. Brown,et al.  Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.

[36]  Donghua Liu,et al.  Cancer chemotherapy with lipid-based nanocarriers. , 2010, Critical reviews in therapeutic drug carrier systems.

[37]  S. Schreier,et al.  Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. , 2008, The Journal of pharmacy and pharmacology.

[38]  R. Maranhão,et al.  Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study , 2008, Cancer Chemotherapy and Pharmacology.

[39]  D. Martincic,et al.  Topoisomerase II inhibitors. , 2005, Cancer chemotherapy and biological response modifiers.

[40]  R. Maranhão,et al.  Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease , 2003, Cancer Chemotherapy and Pharmacology.

[41]  Y. Chen,et al.  Human prostate cancer cells lack feedback regulation of low‐density lipoprotein receptor and its regulator, SREBP2 , 2001, International journal of cancer.

[42]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.

[43]  S. Yamashita,et al.  Marked hypocholesterolemia in a case with adrenal adenoma--enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. , 1995, The Journal of clinical endocrinology and metabolism.

[44]  F. Pileggi,et al.  Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. , 1992, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[45]  R. Geran,et al.  PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS , 1972 .